Misplaced Pages

This is an old revision of this page, as edited by Dylan Flaherty (talk | contribs) at 19:09, 6 September 2010 (bad link). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (February 2009)

Hematide is an investigational synthetic peptide, substituted with polyethylene glycol (thus described as "PEGylated"). It is a novel erythropoietic agent, being an analog of erythropoietin, and has been developed for medical use as a treatment for anemia, now in stage 3 clinical trials. Whether it will be approved is not certain.

The drugs currently used to treat anemia in the United States are epoetin alfa (which mimics the structure of the human glycoprotein which promotes red blood cell development, sold under the names Procrit and Epogen) and darboepoetin alfa (which is a more glycosylated form of epoetin, sold under the name Aranesp). There are similar biologic agents, such as Mircera, sold by Roche in Europe, however "United States patent law currently forbids their sale.

References

1. "Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers" Blood, 15 September 2006, Vol. 108, No. 6, pp. 1830-1834. abstract
2. "Hematide for the Treatment of Anemia: An Expert Interview With Iain C. Macdougall, BSc, MD, FRCP" Medscape Nephrology
3. "Affymax wavers on forecast of Hematide approval" by Marley Seaman Associated Press, July 2, 2008 Boston.com
4. Judge blocks anemia drug sales by Amgen Rival" New York Times February 29, 2008.

This protein-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Orphaned articles from February 2009
• Peptides
• Protein stubs